Biocircuit Technologies Inc.
Atlanta, GA Doing business as Axion PNI Biocircuit Technologies Inc.
- UEI
- E9KLDNMNYJK5
- CAGE
- 8BFM7
- Primary NAICS
- 339112 Surgical and Medical Instrument Manufacturing
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- NAICS codes registered in SAM.gov
- Corporate family
-
-
Biocircuit Technologies Inc.
E9KLDNMNYJK5
- Ampera, Inc. DX1RBZD5BQC5
-
Biocircuit Technologies Inc.
E9KLDNMNYJK5
- SAM.gov registration date
- Physical address
- 1819 Peachtree Road Northeast #350, Atlanta, GA 30309, USA
- Website
- biocircuit.com
- Employees
- 11-50
- Estimated annual revenue
- $1M-$10M
- Industry
-
- Health Care
- Health Care Equipment & Services
- Health Care Providers & Services
- SIC code
- 38 Instruments & Related Products
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Recent federal awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| Lymph tape: a device for simplified lymphovenous anastomosis - project summary lymphedema is a progressive and… | National Heart Lung and Blood Institute | $379,187 | |
| DARPA commercial solutions opening - embedded entrepreneur initiative | Defense Advanced Research Projects Agency | $350,000 | |
| Commercialization readiness for nerve tape: a nerve repair coaptation aid - project summary this sbir… | National Institute of Neurological Disorders and Stroke | $2,372,515 | |
| Spinal reflex conditioning system for enhancing motor function recovery after incomplete spinal cord injury | National Institute of Neurological Disorders and Stroke | $9,174,043 | |
| Microhook nerve tape: a nerve repair coaptation aid | National Institute of Neurological Disorders and Stroke | $4,529,996 |
About Biocircuit Technologies Inc.
Biocircuit Technologies Inc., doing business as Axion PNI, develops and commercializes minimally invasive biomedical devices and diagnostic technologies for federal defense and health research agencies, acting as a prime recipient on federal grants and a prime awardee on federal contracts and Other Transaction agreements. The Atlanta-based for-profit manufacturer is not an SBA-designated small business and competes in full-and-open federal procurements; recent work addresses medical device commercialization and defense electronic system diagnostics through awards from the Defense Advanced Research Projects Agency and the National Institute of Neurological Disorders and Stroke.
Biocircuit's federal footprint centers on two core technical platforms. The company holds a $1.83 million DARPA Other Transaction IDV awarded September 29, 2023, titled Microneedle Arrays for In-Situ Diagnosis of Electronic Systems (MAIDENS), under which DARPA issues task orders for research and development on microneedle array technology for real-time, in-situ monitoring and diagnostics of defense electronic systems. The company also received a $350,000 DARPA definitive contract dated January 28, 2026, for commercialization support under DARPA's Embedded Entrepreneurship Initiative, applying this same microneedle technology to transition prior DARPA-funded research into practical military capabilities, with performance running through January 27, 2027 and an optional extension to 24 months total.
On the medical device side, Biocircuit is prime recipient of a project grant from the National Institute of Neurological Disorders and Stroke awarded September 22, 2023, under the SBIR Commercialization Readiness Pilot program, funding the development and regulatory pathway for Nerve Tape, a sutureless nerve repair device composed of microscale nitinol hooks embedded in a biologic wrap as an alternative to microsuture repair techniques. That award runs through November 30, 2026. Biocircuit also appears as a sub-recipient on a December 2024 Virginia Commonwealth University grant award for Nerve Tape Assisted Gap Management in Peripheral Nerve Repair.
Activity is episodic across the six identified awards spanning 2016 to 2026. DARPA and the National Institute of Neurological Disorders and Stroke together account for all identified work; four awards face ultimate completion within the next twenty-four months, carrying combined potential value of $350 thousand, though the source reports cumulative obligations of $16.6 million across all awards, suggesting prior project-based funding cycles and internal capitalization distinct from the current recompete window. Biocircuit maintains no named subcontractor footprint and does not hold a seat on government-wide vehicles such as GWACs or agency-wide IDIQs.
Quick answers
What is Biocircuit Technologies Inc.'s UEI?
Biocircuit Technologies Inc.'s Unique Entity ID (UEI) in SAM.gov is E9KLDNMNYJK5.
What is Biocircuit Technologies Inc.'s CAGE code?
Biocircuit Technologies Inc.'s CAGE code is 8BFM7.
What is Biocircuit Technologies Inc.'s primary NAICS code?
Biocircuit Technologies Inc.'s primary NAICS code is 339112 (Surgical and Medical Instrument Manufacturing).
Where is Biocircuit Technologies Inc. located?
Biocircuit Technologies Inc.'s physical address in SAM.gov is 1819 Peachtree Road Northeast #350, Atlanta, GA 30309, USA.
Is Biocircuit Technologies Inc. registered in SAM.gov?
Yes. Biocircuit Technologies Inc.'s SAM.gov registration is active through January 14, 2027.
What is Biocircuit Technologies Inc.'s most recent federal award?
Biocircuit Technologies Inc.'s most recent federal grant award is Lymph tape: a device for simplified lymphovenous anastomosis - project summary lymphedema is a progressive and… (R43HL184714), from National Heart Lung and Blood Institute, on August 10, 2026.
On GovTribe
See Biocircuit Technologies Inc.'s full federal record
- Federal contract awards
- IDV awards
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors